Higher Breast Cancer Rates Will Push Treatment Market Beyond $17 Billion by 2021, says GBI Research

Jan 07, 2016, 07:00 ET from GBI Research

LONDON, January 7, 2016 /PRNewswire/ --

The global breast cancer therapeutics market will increase in value from $10.4 billion in 2014 to $17.2 billion by 2021, says GBI Research.

Analysis from business intelligence provider GBI Research - Breast Cancer Therapeutics in Major Developed Markets to 2021 - states that such impressive growth will mostly be down to rapidly rising breast cancer diagnoses caused by an aging population, changing lifestyles and increasing survival rates.

The introduction of several new therapies will help to drive breast cancer treatment market growth by 2021. For a complimentary sample of this research, please visit the GBI Research website.

Analyst Deekshita Allavarapu: "In terms of upcoming breast cancer treatments, the overall pipeline is strong, with 743 products, and the early pipeline has many experimental molecules designed to target novel pathways.

"Promising pipeline drugs include abemaciclib, buparlisib, LEE 011, Olaparib and NeuVax, all of which are expected to be approved within the forecast period and have demonstrated significant clinical benefits in trials. In addition, rapid uptake of premium-priced biologics, such as Perjeta and Kadcyla, in all settings of the disease will contribute to the market growth."

The late-stage breast cancer pipeline is weak, with only 6% of candidates in Phase III of development, and targeted therapies, currently unrepresented by marketed products, almost non-existent within this phase.  

GBI Research's report also states that the market will face some limitations due to patent expirations creating substantial opportunity for generic and biosimilar manufacturers.

Allavarapu continues: "The patents for a number of key breast cancer drugs, including Afinitor, Avastin and Herceptin, are expected to expire during the forecast period. However, the use of combinations of branded therapies in both the early-stage and metastatic settings will increase the Annual Cost of Therapy (ACoT) and offset the impact of patent expiries.

"For example, the ACoT for the combination of Perjeta with Herceptin is three times that of Herceptin monotherapy in both adjuvant and metastatic settings in the US. Therefore, even though Herceptin is set to expire in the near future, this will be offset by the approval of newer combination therapies and the growth of current premium therapies."

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends.

For more information, please contact GBI Research on: +44-161-359-5817

For the full range of market-leading analysis on the pharmaceutical industry, visit GBI Research's report store.

Follow GBI Research online for the latest healthcare industry updates:

Facebook | LinkedIn | Twitter


SOURCE GBI Research